Haemonetics stock performance snapshot after recent weakness Haemonetics (HAE) has drawn investor attention after a period of share price weakness, with the stock down about 9% over the past month and ...

Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter fiscal year 2026, which ended March 28, 2026, are available on the Company's Investor Relations website at ...

Bank of America Global Healthcare Conference 2026 May 12, 2026 11:00 AM EDTCompany ParticipantsChristopher Simon - ...

Investors in Haemonetics Corporation HAE need to pay close attention to the stock based on moves in the options market lately. That is because the June 18, 2026 $40.00 Call had some of the highest ...

Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago. These figures ...

Q4 FY26 earnings call recap: revenue/EPS, FY27 guidance, Persona PLUS momentum, IVT inflection, and tariff risks—read now.

BOSTON, Jan. 14, 2020 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

Haemonetics Corporation HAE is progressing well with its growth strategies like the expansion of the product portfolio within its plasma and Hemostasis Management franchise. However, economic ...

We believe that Haemonetics stock, best known for its blood and plasma supplies and services, is a good buying opportunity at the present time. HAE stock trades near $70 currently and it is, in fact, ...